focus -WSS

focus

author：hotspot 2025-09-28 02:28:48 - browse：43

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

WSS

State of the Union pitch: Bigger Medicare drug price negotiations

Families look for replacement for GSK asthma drug Flovent

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

A new nitrogen execution bill also undermines medical licensing

Community Health Systems hospitals under DOJ investigation

knowledge

focus

focus

Hollywood unions extend contract negotiations for actors

Families look for replacement for GSK asthma drug Flovent

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Cancer drug shortages should be causing more outrage

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Psychedelics group wrestles with new pharma identity

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Walensky prepares to leave CDC — and Congress — behind

Antivenom research: Lessons from HIV applied in search for universal antidote

knowledge

Alabama IVF ruling threatens families facing fatal genetic disease

The Harvard botanist who searched for psychedelics in the Amazon

Alabama hospital puts IVF treatments on hold

Ozempic has benefits for kidney disease as well as diabetes

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Alabama IVF ruling threatens families facing fatal genetic disease

leisure time

Wikipedia

leisure time

focus